Sanofi has lead a round of investment for Enable Injections’ enFuse, an on-body drug-delivery system. Previous investors, including the Cleveland Clinic and CincyTech, and private investors also participated in the round. Enable Injections developed a drug-delivery device that’s designed to deliver doses of biologics.*
Enable Injections set out to create a product that allows a pharmaceutical company to give patients the most positive administration experience possible. The company leverages its device as a way for biopharma companies to differentiate their drugs and improve compliance among users.
John Rice, Enable Injections board member & CincyTech’s director of life sciences, says: “Enable Injections has made significant progress and is now a clinical-stage company with its initial products in human clinical trials. This financing will enable the company to advance to a commercial scale and bring its first products to market. The investment and partnership with Sanofi provide that commercial validation.”
*A biologic is manufactured in a living system such as a microorganism, or plant or animal cells. Most biologics are very large, complex molecules or mixtures of molecules. Many biologics are produced using recombinant DNA technology.
As reported in Drug Delivery Business: http://bit.ly/Sanofi_Enable
News items and features like this appear in the Desang Diabetes Magazine, our free-to-receive digital journal (see below). We cover diabetes news, diabetes management equipment (diabetes ‘kit’ such as insulin pumps and continuous glucose monitoring equipment) and news about food suitable for a diabetic diet including a regular Making Carbs Count column. We just need your email address to subscribe you (it’s free, and you can easily unsubscribe should you wish to).
